STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
The FDA warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharmaceutical companies to inform patients and doctors of the risk, STAT writes.
Key points
- Once again, we will note that our settings have changed to accept postcards and telegrams … The Food and Drug Administration approved a Bayer drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely, STAT notes.
- The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes referred to as an “eye stroke” and is caused by insufficient blood flow to the optic nerve.
- Blue skies, cool breezes, and plenty of chirping birds are enveloping the comfy Pharmalot campus, which is cause to fire up the coffee kettle for yet another cup of stimulation.
Many blood thinners are not used in this setting due to the increased risk of bleeding, but the drug, which will be sold under the brand name Sunharbo, uses a mechanism that is thought to stop the formation of bad clots without increasing the risk of bleeding.
Additional details
- The FDA said it started looking into this risk after researchers in 2024 published an observational study linking Ozempic and Wegovy to the eye condition.
- Continue to STAT+ to read the full story….
- Experts say the data showed a significant advance in an area that has seen little innovation over the past few decades.
- It typically causes sudden vision loss and, in severe cases, can lead to blindness.
- Meanwhile, we have assembled the latest menu of tidbits for you to peruse.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.